Chiron regulatory update

CHIR's Chiron Vision Corp. business unit received FDA approval for Vitrasert Implant, a drug delivery system that provides local, sustained release of ganciclovir ( Roche's Cytovene) to treat cytomegalovirus (CMV) retinitis in people with AIDS.

In July, Chiron Vision filed its NDA, which included data from two Phase III trials demonstrating that the implant offers significant improvement over deferred therapy or standard therapy in delaying the progression of the condition (see BioCentury Extra Feb. 1, 1995). ...